Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

2860 - Immune surveillance reactivation to improve overall survival in small cell lung cancer (SCLC): The randomized IMPULSE study


08 Oct 2016


Poster Display


Michael Thomas


Annals of Oncology (2016) 27 (6): 493-496. 10.1093/annonc/mdw389


M. Thomas1, R. Carter2, S. Ponce Aix3, J. Riera-Knorrenschild4, A. Navarro Mendivil5, M. Domine6, J. Kollmeier7, P. Sadjadian8, R.M. Huber9, M. Wolf10

Author affiliations

  • 1 Internistische Onkologie Der Thoraxtumoren, Thoraxklinik Heidelberg, 69126 - Heidelberg/DE
  • 2 Mologen Ag, MOLOGEN AG, 14195 - Berlin/DE
  • 3 Servicio De Oncologia Medica, University Hospital 12 De Octubre, Madrid/ES
  • 4 Klinik Für Innere Medizin, Klinikum der Philipps Universität Marburg, Marburg/DE
  • 5 Medical Oncology, Vall d`Hebron University Hospital Institut d'Oncologia, 08035 - Barcelona/ES
  • 6 Oncology, University Hospital "Fundacion Jimenez Diaz", 28040 - Madrid/ES
  • 7 Klinik Für Pneumologie, HELIOS Klinikum Emil von Behring GmbH, Berlin/DE
  • 8 Onkologie Und Hämatologie, Johannes Weseling klinikum, 32429 - Minden/DE
  • 9 Thoracic Oncology Centre Munich, LMU Klinikum der Universität München, München/DE
  • 10 Dept. Of Hemato/oncology, Klinik Kassel, 34125 - Kassel/DE


Abstract 2860


The immune surveillance reactivator lefitolimod (MGN1703), a DNA-based Toll-like receptor 9 (TLR9) agonist, was compared to placebo in metastatic CRC (mCRC) patients with disease control after standard induction chemotherapy in the double-blind randomized phase 2 IMPACT study. Lefitolimod showed a superior effect over placebo in exploratory analyses of pretreatment characteristics that identified patients most likely to benefit from lefitolimod. A study in small cell lung cancer (SCLC) patients, IMPULSE, was designed to confirm this preliminary evidence of efficacy in a new, high-mortality-and-unmet-need indication.

Trial design

Trial characteristics: IMPULSE is a randomized, international, multicenter, open-label trial to assess the effect of TLR9-mediated immune surveillance reactivation on overall survival (OS) in extensive-disease (ED) SCLC patients. Secondary endpoints include PFS, response rates, safety, and quality of life (QOL). The baseline stratification factors neuron-specific enolase (NSE) and activated NKT cells are prospectively assessed. 103 patients with objective tumor response following 4 cycles of platinum-based first-line induction therapy were randomized to receive either lefitolimod switch-maintenance therapy or local standard of care in a 3:2 ratio. Upon relapse, patients are receiving appropriate second-line therapy. All patients take part in a comprehensive immune monitoring plan that will evaluate cytokines and chemokines in serum, and the activation status of various immune cell populations. Demographic characteristics: Out of 103 patients, 62 patients were allocated to the treatment arm; 41 to standard of care (control). Median age was 63 years (MGN1703) and 64 years (control). Male/female distribution was 39/22 and 29/12, respectively. Distribution of baseline stratification factors NKT activation (≧3.5%/ 20/≦20) 11/50 and 8/33, respectively. The figures show that patients have been adequately distributed and balanced between the two treatment arms.

Clinical trial identification


Legal entity responsible for the study





R. Carter: Employee at MOLOGEN AG. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings